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The levels of extracellular phospholipase A2
(sPLA2) and TNFa, and cell accumulation were
measured in the pleural washings obtained at
different times following the induction of Escher-
ichia coli lipopolysaccharide (LPS, 100 mg/cavity)
pleurisy in rats. TNFa peaked at 2 hours
(3036 160·3 units/ml) and decreased thereafter.
Conversely, levels of sPLA2 peaked at 48 hours
(1·97 0·64 ng/ml) and were increased further
(14·02 4·16 ng/ml) by pretreatment with anti-
TNFa antibody. Cell accumulation was not affect-
ed by antibody pretreatment. These data indicate
that the sPLA2 enzyme is involved in LPS-induced
pleurisy. The enzyme seems not to be stimulated
by TNFa which may be involved in the down-
regulation of sPLA2 in this model of in￿ amma-
tion.
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Introduction
The extracellular form of phospholipase A2 has
been shown to be involved in several in￿amma-
tory disorders, including those arising from
Gram negative bacterial infections.1,2
Phospholipase A2 (PLA2) activation is a rate
limiting step in the generation of arachidonic
acid, the substrate necessary for eicosanoid
generation. The secreted form of PLA2 (sPLA2
group II) has been found at high levels in the
serum and locally during in￿ammation in ex-
perimental animals and humans,3 and there is
in vitro evidence that its induction is under
cytokine control. 4- 7 Furthermore, sPLA2 has
been proposed to play a role in septic shock.
T o date, however, the relationship between
cytokines and sPLA2 levels in in￿ammatory
exudates and in the serum is still con-
troversial.2,8 It has been shown that intrapleural
injection of LPS into rats elicits an in￿ammatory
response characterized by leucocyte accumu-
lation.9 Furthermore, challenge of isolated gui-
nea pig lung with endotoxin generates TNFa
11
and the presence of TNFa in the bronchoalveo-
lar lavage ￿uid of experimental animals has
been demonstrated following intratracheal ad-
ministration of LPS.12 It appears that tumour
necrosis factor alpha (TNFa) is a cytokine
playing a pivotal role in the development of
endotoxin-induced in￿ammation.10
We have examined whether intrathoracic in-
jection of bacterial endotoxin into rats is capable
of causing the release of sPLA2 and TNFa, and
the potential relationship between this enzyme
andthis cytokine in this modelofin￿ammation.
Materials and Methods
Pleurisy
Pleurisy was induced in en￿urane anaesthetized
male Wistar rats (250±300 g; Charles River,
Milan, Italy) by intrathoracic injection of E. coli
lipopolysaccharide (LPS, 0127:B8; 100 mg/
cavity) in a ￿nal volume of 200 ml. Control
animals received an equivalent volume of phos-
phate buffered saline (PBS). Different groups of
animals were treated with a polyclonal anti- TNF a
antibody (3 mg/kg i.v.; TAB, London) or control
IgG(3 mg/kg i.v.) immediately before the induc-
tion of pleurisy. Animals were killed with CO2
at 2, 6, 24, 48, or 96 hours following the
injection of LPS or PBS. Groups of animals
pretreated with anti-TNFa antibody, or control
IgG, were killed after 2 and 48 hours, the time
required to obtain peak TNFa and sPLA2 levels
respectively. Immediately after sacri￿ce the
thoracic cavity was opened and washed with
2 ml of heparinized (5 UI/ml) sterile saline. The
￿uid volume was collected in graduated tubes
and centrifuged at 125 3 g for 10±15 min. The
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leucocyte count was evaluated. Supernatant
was further centrifuged at 650 3 g for 10±
15 min, immediately frozen and kept at - 208 C
until assayed for TNFa and sPLA2.
Leucocyte count
T otal leucocyte count was evaluated by optical
microscopy in the cell suspension diluted with
Turk’s solution. Differential cell count was
performed by counting air dried smears stained
with Giemsa reagent under an oil immersion
objective. Counts are reported as number of
cells 3 106/cavity.
TNFa determination
TNFa in the cell-free pleural washing was
assessed on WEHI-164 cells by a bioassay using
recombinant human TNFa (Sigma) as the refer-
ence standard, and rabbit anti-murine TNFa
antiserum (Genzyme) which cross reacts with
rat TNFa to assess the speci￿city of TNFa
dependent cytolitic activity.13 TNFa is ex-
pressed as units of TNFa/ml, where one unit is
de￿ned as the quantity required to lyse 50%of
WEHI-164 cells.
PLA2 assay
Asandwich assay for sPLA2 was run according to
the method described by Santos et al.8 with
some modi￿cations. Plates were coated over-
night with a monoclonal anti-human recombi-
nant sPLA2 antibody (BA11), 10 mg/ml,in 50 mM
sodium bicarbonate buffer, pH9.6. Six cycles of
washing with 0.1%w/v Tween-20 in PBS were
done at each step and all incubations were at
48 C. The plates were blocked overnight with
10 mg/ml of gelatin in PBS. Human recombinant
sPLA2 was diluted in 50 nM Tris-HCl, pH 7.5,
0.1% w/v Tween-20, 1% v/v foetal calf serum
(FCS), to obtain the desired dilution, and 0.05 ml
were added to the wells at 48 C for 1 hour (low
temperature decreases non-speci￿c PLA2 bind-
ing). Bound human recombinant sPLA2 was
detected by incubation for 90 min with 0.05 ml
of a 1:2000 dilution of rabbit anti-human recom-
binant sPLA2 (n.207) in assay buffer. Plates were
washed and 0.1 ml of a solution containing
1 mg/ml of tetramethylbenzidine in DMSO,
mixed with 10 ml of acetate buffer (0.1 M, pH
5.0) and 0.125 ml of diluted hydrogen peroxide
(0.2 ml 30% hydrogen peroxide and 7 ml of
water), were added to each well. After 15±
20 min, 0.025 ml of stop solution (H 2SO4, 2 M)
was added and the yellow colour read at 450 nm
by an ELISA reader. sPLA2 in the cell-free pleural
washing was expressed as ng/ml.
Histological analysis
Lungs from control or LPS-injected animals were
removed and ￿xed in neutral buffered formalin
before being embedded in paraf￿n. Sections
(4 mm) were stained with hematoxylin and
eosin.
Statistical analysis
Data are expressed as mean SEMand analysed
with a computerized package for statistical com-
parison.14 T o compare groups of animals, un-
paired two tailed Student’s t test was used. Data
on TNFa were analysed by the Mann±Whitney
test. A P, 0·05 was taken as signi￿cant.
Materials
Recombinant human sPLA2 produced in mam-
malian cells, monoclonal anti-human recombi-
nant sPLA2 antibody (BA11) and rabbit
polyclonal anti-human recombinant sPLA2 anti-
body (n. 217) were a generous gift from Dr J. L.
Browning (Biogen). En￿urane was purchased
from Abbott (Italy). Lipopolysaccharide from E.
coli (serotype 0127:B8), PBS and heparin were
purchased from Sigma (Italy). Antibody to hu-
man TNFa was a generous gift from TAB
London, and has been shown to neutralize rat
TNFa in vitro (TABLondon, unpublished data).
Results
Leucocytes
Following intrathoracic injection of LPS, total
leucocyte count was signi￿cantly increased only
at 48 and 96 hours, while at 6 hours there was
a signi￿cant reduction in the leucocyte count
compared to control value. Polymorphonuclear
count was signi￿cantly increased at 24 and 48
hours, signi￿cantly reduced at 6 hours and
returned to control levels after 96 hours. Mono-
cyte count was signi￿cantly increased at 96
hours, and signi￿cantly reduced below control
levels at 6 and 24 hours (Fig. 1).
TNFa determination
TNFa in the cell-free pleural washing peaked at
2 hours following LPS injection. At the succes-
sive time points, TNFa levels were reduced
progressively, becoming undetectable at 96
hours (Fig. 2).
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Phospholipase A2 levels in the cell-free pleural
washing were detectable at 2 hours, reached
their maximum at 48 hours and were stable up
to 96 hours (Fig. 2).
Pretreatment with anti-TNFa antibody
Levels of TNFa at 2 hours were signi￿cantly
reduced by anti-TNFa antibody (118·4
41·4 units/ml vs 3036 1603 units/ml as deter-
mined by the Mann±Whitney test, P, 0·01,
n= 5). Pretreatment with anti-TNFa antibody
signi￿cantly increased sPLA2 levels at 48 hours
(Fig. 3). Both total and differential cell analysis
were unaffected by antibody pretreatment (data
not shown).
Histological analysis
In the histological sections of lungs obtained
from either PBS or LPS injected animals there
was neither leukocyte in￿ltration, nor alteration
in the cell lining of tissue.
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FIG. 1. Time course of cell accumulation in the pleural space following LPS (100 mg/cavity) injection: (A) total leucocytes; (B)
polymorphonuclear leucocytes; (C) monocytes. Control, open bars; LPS, ® lled bars. P , 0.05; P , 0.01. Student’s t-test,
n= 4±6.
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FIG. 2. Time course of sPLA2 (j ; n = 4±6) and TNFa (u ; n = 3±7) levels in the cell-free pleural washing following LPS
(100 mg/cavity) administration.
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By using a highly speci￿c immunoenzymatic
assay, we have demonstrated the presence of
extracellular sPLA2 group II in the cell-free
pleural washing at different time points follow-
ing LPS injection, providing direct evidence for
a role of this enzyme in the pleurisy triggered
by LPS. In our model, the appearance in the
cell-free pleural washing of increased levels of
sPLA2 was delayed compared to TNFa levels.
Indeed, sPLA2 increased in the cell-free pleural
washing only when TNFa levels started to
decline, and it reached its maximum at 48
hours, when TNFa levels were very low. At the
same time, cells signi￿cantly accumulated: poly-
morphonuclear leucocytes reached their maxi-
mum at 48 hours, and at 96 hours the pleural
washing consisted almost totally of monocytes.
When animals were pretreated with anti-TNFa
antibody, TNFa levels were signi￿cantly re-
duced. However, cell accumulation did not
parallel the increase in TNFa and pretreatment
with anti-TNFa antibody did not affect total and
differential cell count, suggesting that resident
pulmonary cells, stimulated by LPS, may ac-
count for TNFa production and that TNFa is
not involved in LPS-induced leucocyte margina-
tion in the pleural space. These data are
consistent with data reported by others, who
demonstrated that IL-1 and not TNFa is mostly
responsible for LPS-induced neutrophil migra-
tion to an in￿ammatory site.15 Moreover, it is
known that adhesion molecules contribute
greatly to LPS-induced leucocyte margination in
the lung and their expression is under the
control of multiple cytokines.12 Other authors
report that the ability of TNFa inhibitors to
protect animals from ￿ogogen-induced lung
injury is not linked to a reduction in PMN
sequestration.16 In the light of this knowledge,
it is not unexpected that the inhibition of TNFa
alone did not affect leucocyte accumulation.
Surprisingly, when we pretreated animals
with the anti-TNFa antibody, we observed a
strong increase in sPLA2 levels in the cell-free
pleural washing at 48 hours. Thus, it seems that
TNFa does not exercise a positive control on
sPLA2 induction in vivo, rather its inhibition
causes sPLA2 levels to increase further, at least
in this experimental model of pleurisy. Systemic
administration of the antibody allows us to rule
out the hypothesis of any interference of the
antibody with ELISA assay reagents. Although
there is much evidence that in vitro cytokines
are the major inducers of sPLA2 synthesis and
secretion from several different cell types, there
is no direct evidence that in vivo sPLA2 secre-
tion is under cytokine control. A positive
correlation has been found between TNFa and
sPLA2 plasma levels both in human and in
experimental animals challenged with bacterial
endotoxin, as well as an increase in plasma
sPLA2 levels following TNFa injection in
volunteers,1,2 but this evidence has never been
followed by clari￿cation of the in vivo role of
the enzyme. In 1993 synthesis and secretion of
a 14 kDa sPLA2 from guinea pig alveolar macro-
phages was demonstrated and it was found that
the enzyme was not involved in the release of
arachidonic acid metabolites.17 More recently
the same research group has shown that expres-
sion of sPLA2 in guinea pig alveolar macro-
phages is downregulated by an in￿ammatory
stimulus such as FMLP,18 and it has been found
that the release of arachidonic acid metabolites
from guinea pig alveolar macrophages in vivo is
reduced below control levels 24 hours after
pretreatment with LPS.19 Up to now, the role of
sPLA2 in vivo has been unresolved; following
these more recent ￿ndings, it has been sug-
gested that the secreted form of PLA2 might
have a protective role at site of injury. 17- 21
It is noteworthy that 6 hours following LPS
administration there was a signi￿cant reduction
in leucocyte number in the pleural space,
paralleled by a reduction in both granulocyte
and monocyte counts. Although there was
neutrophil accumulation in the lung at 24
hours, the total leucocyte count did not in-
crease since the monocyte count was still
reduced below the control level. This reduction
could be explained by an increased cell adhesiv-
ity which precedes cell accumulation. Indeed,
recent data have demonstrated that injection of
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FIG. 3. Effect of anti-TNFa antibody (3 mg/kg i.v.) on sPLA2
levels at 2 and 48 hours following LPS (100 mg/cavity)
administration (n = 4). Control, open bars; treated, ® lled
bars. P , 0.05. Student’s t-test.
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pleural space of rats causes a bell-shaped cell
accumulation curve. This ￿nding has been
shown to be linked to the increased cell
adhesivity, evoked by high doses of IL-1 and
TNFa.22
In conclusion, our data demonstrate that
following intrapleural injection of endotoxin
into rats, TNFa and sPLA2 group II appear
sequentially in the pleural washings. The early
appearance of TNFa is in agreement with data
reported by others who describe TNFa as an
early response cytokine. The high levels of
sPLA2 in the late phase of the in￿ammation
further suggest a role for the extracellular form
of the enzyme in in￿ammation triggered by
bacterial endotoxins. TNFa is probably pro-
duced by resident pulmonary cells and does not
seem to be directly involved in cell accumula-
tion. TNFa does not stimulate the enzyme
induction, rather there is evidence that its
inhibition increases sPLA2 levels, suggesting that
this cytokine could participate in a mechanism
of downregulation of the enzyme during in￿am-
mation; however, this hypothesis requires
further clari￿cation.
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